Consolidation at LQDA in range of their all time low after FDA issued the biotech company a CRL due to COVID restrictions. After speaking with regulators at the FDA, The company expressed this CRL had nothing to do with the underlying data. Options activity has been healthy. I believe price will increase from here, which is why I have started a position and...
FDA provides preliminary approval for the drug filgotinib not approved, Galapagos will now assume full responsibility for filgotinib in Europe. Gilead will pay EUR 160 million to Galapagos to accelerate commercial activities in Europe. The gap from 19 march 2019 is filled....ready for the turn up..... what do you think?
plenty of news coming up for this name. has all the catalysts coming, phase 3 results, filing for emergency approval and emergency approval itself. just needs the volume to go higher and retest ATH maybe in December
Dropped from $40 to $3 on Phase 3 trial failure wasn’t even an FDA denial. Has facilities and will be focusing on other trials. Total overreaction. PT $20+ The study’s primary safety endpoint was also met.
$BVXV On Major Overreaction Breakout Watch
MSB is developing Ryoncil - an IV stem cell therapy for the treatment of acute graft versus host disease (aGVHD) in paediatrics. aGCHD is a potentially life threatening (up to 70-90% mortality) complication of bone marrow transplants (indicated for leukemia/lymphoma etc). Ryoncil has been accepted by the FDA for priority review with a PDUFA action date of US 30th...
Now like you and many others I'm shocked by NSPR price action, so what could have caused it? Well theres one and that was the FDA IDE approval, yet today was ann that they got the full FDA IDE approval green light. News -Got FDA IDE approval in the US today -Last week they where at LD Micro 500 they gave us some company insights 1: Theres already sales in Brazil...
Okay I'm gonna start off with the news News -NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year. -Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have...
Well seems like we continue the sell off of the Brazil news that I didn't sell. So what news is there to push it higher? Well if ER repeats the same pattern we can suspect them beating EPS and and Beating Revenue. News -Earnings this wednesday, a week early -They are hitting their road map this year www.inspiremd.com -Atm the FDA IDE is awaiting its pr, yet...
This over reaction to news and an approval may result in another handle on this left-facing cup and handle. Best of luck. -zm
All, I think this is a buy and hold over weekend scenario. FDA approval is no joke (well at least in trading ;) lol). I think this is a gap up Monday and overall could double actually based on chart positioning. TA Wise: we are forming an ascending triangle and topping out. However this is a bullish pattern. Very clear on 4H vs 15M we have yet to break full...
Read the news on last two AGEN articles.. approved for FDA and beat the EPS... This is a monthly chart and i can at LEAST see x2 profits ahead.
So today I sold my NCLH and Bitcoin and went into ACST or Acasti Pharma. We made nice gains with NCLH with a killer premarket but leveled off back under closed, but than exploded 6% and going even higher after I sold at 11.22 with my buy at 9.88. Bitcoin has been bouncing between 1-2%, which had nice support at the emas this morning. is why ACST also caught my...
I just started playing with FDA approvals using my pendulum. I don't see anything good coming out of this news event other than a bounce to sell into. Symmetry support is $57.15 held once. Will it twice?? If it doesn't hold this 786 fib (53.99), the door is open to $40.
This idea comes from recent success in a Sprint trade. It was slow in coming, but it did come through very successfully, which is the impetus for this idea of "reading" tickers with binary events. This is purely a news driven idea in which there is no technical reading of the chart what-so-ever. I have no idea if this will be correct, and am really using this...
My dowsing method suggests LLY gets their FDA approval, and the stock will pop, but that in the longer term, this stock is going to breakdown; probably with the entire market. I'm getting that the resistance will be around that $145-46 zone, which would also be a test of the uptrend line from below. Good luck!
BE CAREFUL!! I'm getting bad vibes on the news for tomorrow in this one. This is based on my dowsing work and it suggests a drop of 38%. That would rock it down to about $42.50 FYI I don't know anything about the fundamentals or background on this pending approval, and I really don't know anything about the company, nor do I care. I'm not super confident yet in...